Uribel Tabs

Dosage of Benzoic Acid must be highly individualized, particularly when used for nitrogen binding.

• For Chronic Hyperammonemia (Sodium Benzoate): The typical adult dosage ranges from 250 mg/kg/day to 500 mg/kg/day, administered in equally divided doses (usually 3 to 6 times daily) with meals. The maximum recommended dose is generally 20 grams per day.
• For Topical Antifungal Use: Apply a thin layer of Benzoic Acid/Salicylic Acid ointment to the affected area twice daily. Treatment duration typically lasts 2 to 4 weeks depending on the severity of the infection.
• For Preservative Use: In pharmaceutical compounding, Benzoic Acid is used in concentrations of 0.01% to 0.15%.

Pediatric dosing is critical and must be calculated based on body surface area (BSA) or weight to avoid toxicity.

• Neonates and Infants: For acute hyperammonemia, a loading dose of 250 mg/kg of sodium benzoate (in combination with sodium phenylacetate) is often administered over 90 to 120 minutes, followed by a maintenance infusion of the same dose over 24 hours.
• Children (Chronic Management): Dosing is usually 250 mg/kg/day divided into several doses.
• Safety Note: Benzoic Acid must be used with extreme caution in neonates due to the risk of 'Gasping Syndrome' associated with benzyl alcohol and benzoate derivatives in immature liver systems.

Renal Impairment

Benzoic Acid and its metabolite, hippuric acid, are primarily excreted by the kidneys. In patients with significant renal impairment (GFR < 30 mL/min), the clearance of hippuric acid is reduced, which may lead to metabolic acidosis and increased systemic toxicity. Healthcare providers may reduce the dose by 25% to 50% and monitor blood pH and ammonia levels more frequently.

Hepatic Impairment

Since the conjugation of Benzoic Acid with glycine occurs primarily in the liver, patients with hepatic insufficiency may have a reduced capacity to form hippuric acid. This can lead to an accumulation of unconjugated Benzoic Acid. Dosing should be initiated at the lower end of the spectrum, and liver function tests (LFTs) should be monitored.

Elderly Patients

Geriatric patients often have age-related declines in renal function. Dosing should be conservative, starting at the lower end of the adult range, with careful monitoring of electrolyte balance and renal markers.

• Oral Administration: Oral powder or solutions should be mixed with food or liquid to improve palatability and reduce gastrointestinal irritation. It is often recommended to take doses with a high-calorie, protein-restricted meal as part of a UCD management plan.
• Topical Administration: Wash and dry the affected area before application. Do not cover with an occlusive dressing (plastic wrap) unless directed by a doctor, as this may increase systemic absorption.
• Storage: Store at room temperature (20°C to 25°C / 68°F to 77°F). Keep containers tightly closed to protect from moisture.

If a dose is missed, it should be taken as soon as remembered. However, if it is almost time for the next scheduled dose, skip the missed dose and resume the regular schedule. Do not double the dose to catch up, as this increases the risk of metabolic acidosis.

Signs of Benzoic Acid overdose include:

• Severe nausea and vomiting
• Rapid breathing (hyperventilation) or difficulty breathing
• Metabolic acidosis (indicated by confusion, fatigue, and rapid heart rate)
• Tremors or seizures
• CNS depression

In case of suspected overdose, contact a poison control center or emergency services immediately. Emergency treatment often involves intravenous fluids, bicarbonate therapy to correct acidosis, and in severe cases, hemodialysis to remove benzoate and hippuric acid from the blood.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop the medication without medical guidance, as ammonia levels can rise rapidly and dangerously.

Patients taking systemic Benzoic Acid (Sodium Benzoate) frequently report gastrointestinal and metabolic symptoms:

• Nausea and Vomiting: This is the most common side effect, occurring in up to 25% of patients. It is often related to the salty taste and gastric irritation caused by high doses.
• Anorexia (Loss of Appetite): Many patients find it difficult to maintain adequate caloric intake due to the taste and GI distress.
• Skin Irritation (Topical): When applied to the skin, redness, stinging, or a mild burning sensation is common, especially during the first few days of use.

• Abdominal Pain: Localized cramping or discomfort in the stomach area.
• Headache: Mild to moderate headaches may occur as the body adjusts to the nitrogen scavenging process.
• Irritability: Particularly in pediatric patients, which may be a sign of fluctuating ammonia levels or the medication itself.
• Lethargy: A feeling of tiredness or lack of energy.

• Hypokalemia: Low potassium levels in the blood, which can cause muscle weakness or heart rhythm disturbances.
• Disorientation: Mild confusion or 'brain fog' that is not directly attributable to hyperammonemia.
• Urticaria: Hives or an itchy skin rash, indicating a mild allergic sensitivity.

> Warning: Stop taking Benzoic Acid and call your doctor immediately if you experience any of these serious symptoms.

• Metabolic Acidosis: Characterized by rapid, deep breathing (Kussmaul breathing), extreme fatigue, confusion, and a fruity odor on the breath. This occurs when Benzoic Acid levels exceed the body's capacity to conjugate it with glycine.
• Anaphylaxis: Severe allergic reactions including swelling of the face, lips, or tongue, difficulty swallowing, and severe wheezing.
• Seizures: Any new or worsening seizure activity requires emergency evaluation.
• Gasping Syndrome (Neonates): A life-threatening condition in newborns characterized by metabolic acidosis, respiratory distress, and CNS dysfunction. This is often linked to the preservative benzyl alcohol but is a critical risk for all benzoate-related compounds in infants.
• Cerebral Edema: Swelling of the brain, which may manifest as severe headache, vomiting, and altered consciousness.

Prolonged use of Benzoic Acid, especially in the management of urea cycle disorders, requires monitoring for:

• Nutritional Deficiencies: Specifically glycine depletion. Because Benzoic Acid requires glycine for excretion, chronic use can deplete the body's stores of this essential amino acid, potentially affecting protein synthesis and growth in children.
• Chronic Gastritis: Persistent irritation of the stomach lining due to the acidic nature of the compound.
• Electrolyte Imbalance: Chronic shifts in sodium and potassium levels due to the high sodium load in sodium benzoate formulations.

There are currently no formal FDA Black Box Warnings specifically for Benzoic Acid as a single agent; however, the combination product Ammonul (Sodium Benzoate/Sodium Phenylacetate) carries significant warnings regarding the risk of Acute Ammonia Toxicity if the infusion is not managed correctly, and the risk of Neurotoxicity if dosage limits are exceeded. Healthcare providers must ensure that the patient's ammonia levels are monitored hourly during acute treatment.

Report any unusual symptoms or changes in mental status to your healthcare provider immediately. Regular blood tests are necessary to ensure the medication is working safely.

Benzoic Acid is a potent pharmacological agent that requires strict medical supervision. It is not a 'simple' preservative when used at therapeutic doses. Patients and caregivers must be aware that Benzoic Acid does not cure urea cycle disorders; it only helps manage the symptoms by removing excess nitrogen. If the underlying cause of hyperammonemia is not addressed (e.g., through diet or other medications), ammonia can still reach toxic levels.

No FDA black box warnings for Benzoic Acid as a standalone ingredient. However, clinicians must adhere to the warnings associated with branded nitrogen scavengers, which emphasize the risk of over-dosage leading to metabolic acidosis and the critical need for specialized center management.

• Allergic Reactions / Anaphylaxis Risk: Patients with a known hypersensitivity to Benzoic Acid, sodium benzoate, or any component of the formulation should avoid use. Cross-sensitivity with other benzoates (like parabens) is possible.
• Metabolic Acidosis: Benzoic Acid is an organic acid. Excessive accumulation in the blood can lower the pH, leading to life-threatening acidosis. This is particularly risky in patients with underlying renal or hepatic disease.
• Sodium Load: Sodium benzoate contains a significant amount of sodium (approximately 160 mg of sodium per gram of sodium benzoate). This must be accounted for in patients with congestive heart failure (CHF), hypertension, or severe renal impairment where sodium restriction is necessary.
• Glycine Depletion: Because Benzoic Acid conjugates with glycine, it can cause a secondary deficiency of this amino acid. Glycine is necessary for many bodily functions, including the synthesis of glutathione, an important antioxidant.

Patients on Benzoic Acid therapy require frequent laboratory monitoring to ensure safety and efficacy:

• Plasma Ammonia Levels: To ensure the nitrogen scavenging is effective.
• Blood pH and Bicarbonate: To monitor for signs of metabolic acidosis.
• Serum Electrolytes: Specifically sodium and potassium levels.
• Plasma Amino Acids: To monitor glycine levels and ensure other essential amino acids are balanced.
• Renal and Hepatic Function: Periodic BUN, Creatinine, and LFTs.

Benzoic Acid may cause dizziness, lethargy, or confusion in some patients. Patients should not drive or operate heavy machinery until they know how the medication affects them. If confusion or disorientation occurs, it may be a sign of high ammonia or medication toxicity, and medical help should be sought.

Alcohol should be avoided while taking Benzoic Acid. Alcohol can stress the liver's metabolic capacity and may interfere with the conjugation process. Furthermore, alcohol can exacerbate the gastrointestinal side effects of the medication.

Benzoic Acid should never be stopped suddenly in patients with urea cycle disorders. Sudden discontinuation can lead to a rapid and potentially fatal 'rebound' increase in ammonia levels (hyperammonemic crisis). If the medication must be stopped, it should only be done under the direct supervision of a metabolic specialist, usually in a hospital setting.

> Important: Discuss all your medical conditions, including any history of heart, kidney, or liver disease, with your healthcare provider before starting Benzoic Acid.

• Corticosteroids (High Dose): While not strictly contraindicated, the use of high-dose steroids can increase protein catabolism (breakdown), which significantly increases the nitrogen load and ammonia production, potentially overwhelming the capacity of Benzoic Acid to scavenge nitrogen.
• Valproic Acid: This anticonvulsant is known to inhibit the urea cycle and can cause hyperammonemia even in healthy individuals. Combining Valproic Acid with Benzoic Acid is generally avoided as it works against the therapeutic goal.

• Probenecid: This medication, used for gout, inhibits the renal tubular secretion of many organic acids. Probenecid can significantly reduce the excretion of hippuric acid (the metabolite of Benzoic Acid), leading to toxic accumulation of benzoate in the blood.
• Penicillins and Cephalosporins: Some antibiotics compete for the same renal secretory pathways as hippuric acid. This can potentially slow the elimination of Benzoic Acid, increasing the risk of side effects.
• Salicylates (Aspirin): High doses of aspirin can compete for protein binding sites and metabolic pathways. Furthermore, both are organic acids, and their combination can increase the risk of metabolic acidosis.

• Diuretics (Loop and Thiazide): These can cause electrolyte imbalances (like hypokalemia) that may be exacerbated by the sodium load and metabolic shifts associated with Benzoic Acid.
• Cisplatin: This chemotherapy agent is nephrotoxic and can reduce the renal clearance of Benzoic Acid metabolites.

• High-Protein Foods: The most critical 'interaction' for Benzoic Acid is with dietary protein. Patients taking Benzoic Acid for UCDs must follow a strict, low-protein diet. Consuming high amounts of protein will produce more ammonia than the medication can handle.
• Dairy Products: While not a direct chemical interaction, the high protein content in dairy must be carefully managed.

• Amino Acid Supplements: Specifically, supplements containing large amounts of glutamine or arginine should only be taken under medical supervision, as they directly impact the urea cycle.
• St. John's Wort: While no direct interaction is documented, St. John's Wort can induce various CYP enzymes; however, Benzoic Acid is primarily metabolized via conjugation, making this interaction less likely but still worth monitoring.

• Urinary Ketone Tests: Benzoic Acid metabolites can sometimes cause false-positive results in certain urinary ketone tests that use the nitroprusside reaction.
• Liver Function Tests: Benzoic Acid was historically used as a test for liver function; therefore, its presence can interfere with specialized metabolic assays.

For each major interaction, the mechanism typically involves either competitive inhibition of renal secretion or metabolic competition for glycine. The clinical consequence is usually an increased risk of Benzoic Acid toxicity (acidosis) or a decrease in the efficacy of nitrogen scavenging (rising ammonia).

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter pain relievers and cold medications.

Benzoic Acid must NEVER be used in the following circumstances:

• Severe Hypersensitivity: Any patient with a documented history of anaphylaxis or severe skin reactions to Benzoic Acid or sodium benzoate.
• Acute Renal Failure: In cases where the kidneys are not producing urine (anuria), Benzoic Acid cannot be excreted, and its use will rapidly lead to fatal metabolic acidosis.
• Inborn Errors of Metabolism with No Glycine Availability: In extremely rare metabolic conditions where glycine synthesis is completely absent, Benzoic Acid cannot be metabolized into hippuric acid and will be ineffective and toxic.

Conditions requiring careful risk-benefit analysis include:

• Congestive Heart Failure (CHF): Due to the high sodium content of sodium benzoate, which can cause fluid retention and worsen heart failure symptoms.
• Pre-existing Metabolic Acidosis: If a patient is already in an acidotic state (e.g., from diabetic ketoacidosis), adding Benzoic Acid will worsen the condition.
• Severe Hepatic Cirrhosis: While Benzoic Acid is used for hyperammonemia (often caused by liver issues), in end-stage cirrhosis, the liver may not be able to conjugate the drug, leading to systemic toxicity.

Patients who are allergic to the following substances may also react to Benzoic Acid:

• Parabens (Methylparaben, Propylparaben): Commonly used as preservatives in cosmetics and pharmaceuticals.
• Cinnamon and Cloves: These contain natural benzoates and related compounds.
• Salicylates: Some patients with 'aspirin-sensitive asthma' or the 'aspirin triad' may also show sensitivity to benzoates.

> Important: Your healthcare provider will evaluate your complete medical history, including any allergies and your kidney and heart function, before prescribing Benzoic Acid.

FDA Pregnancy Category C. There are no adequate and well-controlled studies of Benzoic Acid in pregnant women. Animal reproduction studies have shown some evidence of fetal harm at very high doses.

• Trimester-Specific Risks: During the first trimester, the risk of malformation is unknown. In the third trimester, there is a theoretical risk that high benzoate levels could compete with bilirubin for albumin binding sites, potentially increasing the risk of neonatal jaundice (kernicterus) if administered just before delivery.
• Clinical Consideration: Benzoic Acid should only be used during pregnancy if the potential benefit (preventing life-threatening hyperammonemia in the mother) outweighs the potential risk to the fetus.

It is not known whether Benzoic Acid is excreted in human milk. However, because many drugs are excreted in milk and because of the potential for serious adverse reactions in nursing infants (such as metabolic acidosis), a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Benzoic Acid is widely used in pediatric populations for the management of urea cycle disorders. However, it is associated with significant risks in the very young:

• Neonates (0-28 days): Extreme caution is required. The 'Gasping Syndrome' is a primary concern. Neonates have immature liver and kidney function, making them much more susceptible to benzoate toxicity.
• Growth Effects: Chronic use of nitrogen scavengers can lead to branched-chain amino acid depletion, which may impair normal growth and development. Height and weight must be monitored closely.

Clinical studies of Benzoic Acid did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

In patients with impaired renal function, the clearance of hippuric acid is significantly reduced.

• Mild to Moderate: Monitor blood pH and ammonia levels every 4-6 hours during acute treatment.
• Severe/Dialysis: Benzoic Acid and hippuric acid are dialyzable. Patients on hemodialysis may require supplemental doses after treatment, but the primary dose must be reduced to avoid accumulation between sessions.

Since the liver is the primary site of glycine conjugation, patients with hepatic impairment (Child-Pugh Class B or C) may experience higher levels of unconjugated Benzoic Acid. This increases the risk of CNS toxicity and acidosis. Frequent monitoring of liver enzymes and plasma benzoate levels (if available) is recommended.

> Important: Special populations require individualized medical assessment and often require management by a team of specialists, including geneticists, hepatologists, and neonatologists.

Benzoic Acid acts as a pro-drug for nitrogen excretion. The molecular mechanism involves two steps:

1. 1Activation: Benzoic Acid is converted to its active thioester form, benzoyl-CoA, by the enzyme acyl-CoA synthetase.
2. 2Conjugation: Benzoyl-CoA then reacts with glycine. The enzyme glycine N-acyltransferase transfers the benzoyl group to the amino group of glycine, forming hippuric acid (N-benzoylglycine) and releasing Coenzyme A.

This pathway is significant because it provides a 'bypass' for the urea cycle. Under normal conditions, nitrogen is removed via the synthesis of urea. In patients with urea cycle defects, this pathway is blocked. By forming hippuric acid, the body can 'package' nitrogen (as part of the glycine molecule) and excrete it via the kidneys. One mole of Benzoic Acid removes one mole of nitrogen.

• Dose-Response: There is a linear relationship between the dose of Benzoic Acid and the amount of hippuric acid excreted, provided that glycine levels are sufficient.
• Onset of Action: In acute hyperammonemia, the onset of ammonia reduction is typically seen within 1 to 2 hours of starting an intravenous infusion.
• Duration: The effect lasts as long as the medication is present and glycine is available. Once the drug is cleared (within 12-24 hours), nitrogen scavenging stops.

| Parameter | Value |

|---|---|

| Bioavailability | >90% (Oral) |

| Protein Binding | 70% - 90% (Primarily Albumin) |

| Half-life | 2 - 4 hours (Normal function) |

| Tmax | 1 - 2 hours |

| Metabolism | Hepatic/Renal Glycine Conjugation |

| Excretion | Renal (>95% as Hippuric Acid) |

• Molecular Formula: C7H6O2
• Molecular Weight: 122.12 g/mol
• Solubility: Slightly soluble in water; more soluble in hot water, alcohol, and ether.
• Structure: Consists of a benzene ring with a carboxyl group attached. It is the simplest aromatic carboxylic acid.

Benzoic Acid is primarily classified as a Nitrogen Binding Agent [EPC]. It is also grouped with Antifungals (topical) and Pharmaceutical Preservatives. Related medications in the nitrogen binding class include Sodium Phenylbutyrate and Glycerol Phenylbutyrate, which follow a similar 'scavenging' logic but utilize a different amino acid (glutamine) for excretion.